



**JANUARY 09**  
**IN THIS ISSUE**

Bionomics  
CEO Report

BNC210 Update:  
Safety Studies  
Completed

BNC105:  
Austin Health  
on Board

Profile -  
Dr Jorgen Mould

# BIONOMICS



## CEO Report

Dear Shareholders,

**Welcome to the first edition of Bionomics NOW for 2009. Much has been accomplished since our last update.**

Before reviewing Bionomics' progress over the past quarter I would like to remind shareholders of the fast approaching due date for the exercise of BNOOB options this month. The last day for exercise of the options is 31 January and the options will cease trading on the ASX on 23 January. This important funding from the exercise of options will be used to support the continued clinical development of BNC105.

This quarter we welcome Mr Chris Fullerton as a Non-Executive Director of Bionomics. Mr Fullerton has extensive background in investment, management and investment banking and is a highly experienced company director. He is currently the Managing Director of Mandalay Capital Pty Limited, an investor in listed securities and private equity, Executive Director of Avanti Capital Limited, a recently established advisory firm focusing on the life sciences sector and is a Non-Executive Director of CordLife Limited.

On 28 November the Australasian Investor Relations Association (AIRA) announced its annual awards which are voted by domestic and international analysts and funds managers. Bionomics was voted third in the category "Best investor relations by a company out of the ASX300". In 2009 Bionomics will continue to focus on investor communications as a priority, keeping shareholders abreast of the latest developments in the Company and the progress of its drug candidates.

**The current BNC105 clinical trial continues to proceed as anticipated, with encouraging results.** On 5 November we announced that a fourth clinical centre, Austin Health based in Melbourne, has been initiated. Austin Health is participating in the final stage of the trial. As the trial progresses towards its conclusion there will be a requirement to recruit greater numbers of patients to confirm the dose to be selected for Phase II trials. It is important that this recruitment proceed as smoothly as possible and it is very pleasing to see that Austin Health is now part of the team to ensure that recruitment remains on track. We believe that BNC105 has considerable commercial potential and the economic downturn has increased both the rate and value of licensing deals being done.



CEO

Our second drug candidate, BNC210 made good progress through the steps of scale-up and manufacture and completion of this process under GMP was announced on 9 July. Completing scale-up and manufacture was critical for the timely conclusion of the pivotal safety studies. In March we commenced the formal pre-clinical safety and tolerability program for anti-anxiety drug candidate BNC210 and last month were able to announce that these studies were now completed. **The completion of this program is a key milestone in the drug development process for BNC210, with Bionomics on track to make regulatory submissions to enable clinical development.**

These studies with BNC210, confirmed that BNC210 does indeed have a broad therapeutic window in animal tests. We believe that BNC210 has the potential to be an improved anxiolytic for the treatment of both acute and generalized anxiety disorders, and in the early treatment of depression in combination with anti-depressants. The treatment of anxiety disorders is a significant market opportunity, with a value as high as US\$15 billion pa, which the profile of BNC210 suggests it is ideally placed to meet.

Finally, we have profiled Dr Jorgen Mould in this edition of Bionomics NOW. Jorgen is one of the scientists engaged in our collaboration with Merck Serono and leads the biology effort with particular emphasis on early screening of compounds for blockade of the Kv1.3 ion channel. This ion channel is a key pathway for activation of the cells responsible for nerve cell damage in Multiple Sclerosis.

We look forward to reporting on the next quarter's achievements and once again, I would like to take this opportunity to thank you for your continued support. ●

Dr Deborah Rathjen Chief Executive Officer



## BNC105 Trial Update: Austin Health Now on Board

On 5 November Bionomics announced that a fourth clinical centre, Austin Health based in Melbourne, had been initiated and that Austin Health is participating in the final stage of the ongoing clinical trial of anti-cancer drug BNC105. Austin Health joins other clinical sites within the Cancer Trials Australia network at the Royal Melbourne Hospital, the Peter MacCallum Cancer Centre and the Western Hospital.

Dr Geoffrey Chong, lead investigator for the trial at Austin Health said "We are very pleased to open the trial at Austin Health and for our patients to have access to this interesting new agent".

The current BNC105 clinical trial is progressing well, with BNC105 demonstrating preliminary indications of biological effect as determined by DCE-MRI and CT scans. ●

If you would like to receive your Newsletter via eNewsletter please email [investorrelations@bionomics.com.au](mailto:investorrelations@bionomics.com.au)



J\*M

## BNC210 Update: Pivotal Safety Studies Completed

On 17 December 2008 Bionomics announced the completion of its pivotal safety and tolerability evaluation studies in animals of anti-anxiety compound BNC210. The completion of this program is a key milestone in the drug development process for BNC210, as many compounds fail at this point. Bionomics is on track to make regulatory submissions to enable clinical development.

CLASS	NO SEDATION	NO ADDICTION	NO MEMORY IMPAIRMENT	FAST ACTING	NO DRUG-DRUG INTERACTION
BNC210	✓	✓	✓	✓	✓
Valium	✗	✗	✗	✓	✓
Prozac	✓	✓	✓	✗	✗

Dr Sue O'Connor, BNC210 Program Leader commented, "Preclinical data shows that in animals BNC210 is able to reduce anxiety without the common side effects of current anxiety drugs which include side effects such as drowsiness, impairment of memory and motor function. In addition, BNC210 has been shown to be fast-acting and effective with a single daily dose. In addition to the just completed safety studies, other recent animal studies with BNC210 have shown that BNC210 affects regions of the brain involved in anxiety and have provided biomarkers for evaluation in the clinical setting. With this information a clinical trial can be envisaged which provides an early opportunity for proof-of-concept of BNC210 in man." ●


## Profile - Dr Jorgen Mould

Dr Jorgen Mould\* commenced his position as Senior Research Scientist at Bionomics in 2005. An ion channel biologist with a special interest in ion channels and disease, Dr Mould is leading the development of Bionomics' Multiple Sclerosis (MS) Kv1.3 program.

"I have always wanted to do research that has a direct clinical application and my work has allowed me to apply my skills to something that I feel will be a huge benefit to MS patients," commented Dr Mould.

"Our team is very excited about our collaboration with Merck Serono and the Kv1.3 ion channel as a target for the treatment of MS because it offers the potential for a treatment that is more patient friendly (it can be administered as a tablet) with fewer side effects than current treatments (often painful injections)."

Prior to joining Bionomics, Dr Mould worked at Northwestern University in Chicago, USA and the University of Queensland. He has a Bachelor of Science with Honours (Biochemistry) from the University of Queensland and he completed his PhD in Neuroscience at the John Curtin School of Medical Research, ANU. ●



### Contact Bionomics

31 Dalgleish Street  
Thebarton, SA 5031  
Australia

Tel: +61 8 8354 6101

Deborah Rathjen  
CEO & Managing  
Director

[drathjen@bionomics.com.au](mailto:drathjen@bionomics.com.au)

### See Bionomics

9-11 February 2009  
BIO CEO and  
Investor Forum  
New York, USA

15-22 April 2009  
AACR  
Denver, Colorado, USA

29 May - 2 June 2009  
ASCO  
Orlando, Florida, USA

**Factors Affecting Future Performance** This publication contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this publication that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105 and BNC210, its drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this publication.